Avidity Biosciences (NASDAQ: RNA) is seeking accelerated regulatory approval for Del-Zota, its investigational drug for Duchenne Muscular Dystrophy (DMD) patients amenable to exon 44 skipping. Promising clinical trial data demonstrating significant improvements in dystrophin production and functional measures have positioned the company for a potential market entry and garnered strong analyst ratings, despite recent stock fluctuations related to financing activities.

Avidity Biosciences Advances Del-Zota Towards Accelerated FDA Approval for Duchenne Muscular Dystrophy

Avidity Biosciences (NASDAQ: RNA) is progressing its investigational drug, Del-Zota (also known as delpacibart zotadirsen), towards accelerated regulatory approval by the U.S. Food and Drug Administration (FDA) for the treatment of Duchenne Muscular Dystrophy (DMD) in patients amenable to exon 44 skipping. The company’s strategic move follows the release of promising clinical data, fueling optimism within the Biotechnology Sector.

The Event in Detail: Del-Zota’s Path to Approval

Avidity Biosciences is on track to submit a Biologics License Application (BLA) to the FDA for Del-Zota under the Accelerated Approval pathway by the end of 2025. This expedited process is supported by the FDA’s prior granting of Breakthrough Therapy, Rare Pediatric Disease, Orphan Drug, and Fast Track designations to Del-Zota, underscoring the significant unmet medical need it addresses.

Recent clinical data from the EXPLORE44 and EXPLORE44-OLE trials, released in September 2025, showcased compelling results. Participants treated with Del-Zota for approximately one year exhibited a reversal of disease progression and measurable functional improvements when compared to natural history data. Specifically, the drug led to statistically significant increases of approximately 25% of normal dystrophin production, restoring total dystrophin up to 58% of normal levels. Furthermore, creatine kinase (CK) levels, a key biomarker for muscle damage, rapidly reduced by over 80% from baseline and were sustained at near-normal levels throughout the 16-month evaluation period. Functional endpoints, including Time to Rise from Floor, 4-Stair Climb, Performance of Upper Limb, and 10-Meter Walk/Run Test, also showed notable improvements.

Analysis of Market Reaction and Financial Strategy

The prospect of Del-Zota’s accelerated approval has largely resonated positively with investors and analysts. Avidity Biosciences’ stock has surged over 55% in the past six months, reflecting strong market confidence in its pipeline. Following the positive clinical data announcement on September 10, 2025, RNA stock saw an initial rise of 2%.

However, the company’s recent financial maneuvers have introduced some volatility. Avidity Biosciences launched a public offering of common stock to sell up to $500 million worth of shares, aiming to secure funding beyond 2027. This $500 million cash raise, intended to bolster the company’s already robust financial position, resulted in its stock closing down 11% on September 11, 2025, as is common with such dilution events. As of June 30, 2025, the company reported cash, cash equivalents, and marketable securities totaling $1.2 billion, further supplemented by approximately $185.5 million from an at-the-market offering program and a successful $345 million public offering, surpassing its initial target.

Analyst sentiment remains largely positive. Seeking Alpha maintains a "Strong Buy" rating on RNA, while Goldman Sachs has resumed coverage with a "Buy" rating, and Cantor Fitzgerald maintains an "Overweight" rating. Analysts at BMO Capital Markets anticipate a "smooth" approval process for Del-Zota, given the current lack of other approved exon-44-skipping treatments for DMD44.

Broader Context and Implications

Del-Zota represents an innovative approach as an Antibody-Oligonucleotide Conjugate (AOC), a new class of RNA therapeutics. Its success in demonstrating functional improvements and securing multiple FDA designations highlights the potential of this platform for treating rare genetic diseases. This development could boost investor confidence in novel RNA-based treatment platforms and encourage further investment and research in targeted therapies for conditions with high unmet medical needs. The global Duchenne Muscular Dystrophy market is projected to grow to $7.4 billion by the end of 2034, with approximately 7% of DMD patients amenable to exon 44 skipping.

The potential entry of Del-Zota into the market would position Avidity Biosciences as a significant player alongside established companies like Sarepta Therapeutics, which currently dominates the market with multiple exon-skipping therapies and gene therapy treatments. If approved, Del-Zota could enable Avidity Biosciences to transition into a commercial-stage company around 2026, marking a major inflection point for the firm as it aims for three BLA filings of its AOCs within a 12-month period.

Looking Ahead

Investors will be closely monitoring the progress of Del-Zota’s BLA filing with the FDA by year-end 2025 and the subsequent marketing approval decision. While the Accelerated Approval pathway streamlines the process, there is no guarantee of final FDA marketing approval.

Beyond Del-Zota, Avidity Biosciences has a robust pipeline. The company is advancing Del-Brax for facioscapulohumeral muscular dystrophy (FSHD), with biomarker results from its Phase 1/2 FORTITUDE study expected in Q2 2026, potentially leading to a BLA filing in H2 2026. Another candidate, Del-Desiran, is being evaluated for myotonic dystrophy type 1 (DM1), with data from the MARINA-OLE trial expected in Q4 2025 and topline results from the Phase 3 HARBOR trial in Q2 2026. These upcoming catalysts, alongside ongoing regulatory and clinical trial risks, will be key factors to watch in the coming quarters for Avidity Biosciences and the broader Biotechnology Sector.